Top-Selling Vaccine Made Cheap Shows Challenge to Merck: Health
This article is for subscribers only.
Asia’s biggest vaccine maker is working on a string of new low-priced offerings that threaten to undercut brands from the world’s biggest pharmaceutical companies.
Serum Institute of India Ltd., which makes vaccines injected in 65 percent of the world’s children, is targeting newer vaccines, including one for the human papillomavirus that could be available in late 2018 and sell at a third of the price of Merck & Co.’s blockbuster Gardasil. Also in development are vaccines for types of severe diarrhea and pneumonia.